Guidant's DISCOVERY II pacemaker gets US approval:
This article was originally published in Clinica
Executive Summary
Guidant has received US FDA approval for its DISCOVERY II single sensor pacemaker. The device will complement another of the company's sensor products, the PULSAR MAX pacemaker. The DISCOVERY II is designed to simplify clinician interaction with a pacemaker, enabling physicians to easily and efficiently perform comprehensive tests and follow-up operations. The device also provides a concise report that presents information needed for patient management.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.